Please assess the completion status of the following clinical trial:

Trial Title: OCS-01 in Treating Inflammation and Pain in Post-cataract Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Provide written informed consent, approved by the appropriate ethics committee;~2. Be able to comply with the study requirements and visit schedule;~3. Be at least 18 years of age of either sex or any race;~4. Be planning to undergo unilateral cataract extraction via phacoemulsification and PCIOL implantation in the study eye;~5. Have an anterior chamber cell score ≥ 2 at Visit 2 (Day 1 \[18 to 30 hours post-uncomplicated cataract surgery without vitreous loss\]);~6. Have a pin-hole visual acuity (VA) without any other correction \> 20 letters (approximately 20/400) in the operative eye and \> 35 letters (approximately 20/200) in the fellow eye as measured using an Early Treatment for Diabetic Retinopathy Study (ETDRS) chart at Visit 1 (Day -1 to Day -28 \[prior to surgery\]);~7. Have a negative urine pregnancy test at Visit 1 (Day -1 to Day -28 \[prior to surgery\]),~Exclusion Criteria:~1. Have a known sensitivity or allergy to dexamethasone, corticosteroids, or any of the study medication's components;~2. Be monocular;~3. Have any intraocular inflammation (e.g. white blood cells or flare) present in either eye at the Visit 1 (Day -1 to Day -28 \[prior to surgery\]) slit lamp examination;~4. Have a score \> 0 on the Ocular Pain Assessment at Visit 1 (Day -1 to Day -28 \[prior to surgery\]) in the study eye;~5. Use anti-inflammatory agents, analgesics/pain relievers (including opioids, narcotics, and other pain medications), or immunomodulating agents, systemically or in either eye, and/or use medications for benign prostatic hyperplasia (BPH), from the washout period through the duration of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OCS-01 1.5% mg/mL QD (Type: EXPERIMENTAL): eye drops
- OCS-01 1.5% mg/mL BID (Type: EXPERIMENTAL): eye drops
- Placebo (Vehicle) BID (Type: PLACEBO_COMPARATOR): eye drops

Based on this trial design, predict the completion outcome and termination type (if applicable).